Tirzepatide 30mg GIP/GLP-1 Receptor Agonist

Tirzepatide is a dual GIP and GLP-1 receptor agonist that has been studied for its effects on glucose regulation, insulin signalling, appetite-related pathways and body-weight regulation. Tirzepatide is the active ingredient in Mounjaro and Zepbound, which have approved indications in certain markets.

Research areas include: GIP and GLP-1 receptor signalling, glucose metabolism, insulin sensitivity, appetite regulation, body-weight regulation and cardiometabolic health. The specific 30mg self-mix vial shown here is not equivalent to an approved commercial tirzepatide formulation, and its quality, safety and efficacy would need to be established separately.

Important: Tirzepatide is a regulated prescription medicine. In South Africa, SAHPRA has specifically warned about unregistered, compounded and falsified tirzepatide products and has taken enforcement action against unlawful manufacturing and distribution of unregistered GLP-1/GIP products. This product description is for research/informational purposes and is not intended to diagnose, treat, cure or prevent any disease or medical condition.

The Certificate of Analysis for lot GX-2026 confirms an HPLC purity of 99%+ and identity confirmed by mass spectrometry.

The Safety Data Sheet describes handling, storage and disposal information for this research compound. Always follow standard laboratory safety practice.